NEW YORK, Sept. 18, 2024 – PRESS RELEASE – Tilray Medical, a division of Tilray Brands Inc and a global leader in medical cannabis, empowering the therapeutic alliance between patients and health care practitioners to make informed individualized health decisions, announced the launch of Redecan EU-GMP certified medical cannabis products in Australia.
“The launch of Redecan, a premium cannabis brand, in Australia is another significant milestone for Tilray Medical, as we relentlessly pursue our vision of making high-quality medical cannabis products accessible to patients worldwide,” said Denise Faltischek, chief strategy officer and head of International at Tilray Brands. “The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and health care practitioners to find the optimal therapeutic solutions.”
Jonathan Trodden, director of Tilray Medical Australia, said, “We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.”
The following Redecan products are now available for medical cannabis patients in Australia:
- Redecan PC THC28 Purple Churro – 15 grams
- Redecan SA THC28 Space Age Cake – 15 grams
Tilray continues to be one of the leading providers of EU-GMP-certified medical cannabis to patients, physicians, pharmacies, hospitals, governments and researchers across the globe, and now offers a comprehensive portfolio of THC and CBD products in more than 20 countries.
In furtherance of its mission, Tilray has supported medical trials globally studying the efficacy of medical cannabis as a treatment for indications including fibromyalgia, pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol-use disorders.
